Ingenol-3-acylates I
The invention relates to compounds of general formula (I) wherein R is (C 1 -C 7 )alkyl, (C 2 -C 7 )alkenyl or (C 2 -C 7 )alkynyl; wherein R is substituted with R1; and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, for preventing, treating or ameliorating diseases or conditions responsive to stimulation of neutrophil oxidative burst, responsive to stimulation of keratinocyte IL-8 release or responsive to induction of necrosis.
1. A compound of the general formula I
wherein R is (C 1 -C 7 )alkyl, or (C 2 -C 7 )alkenyl; wherein R is substituted one or more times with substituents independently selected from R1;
wherein R1 represents (C 1 -C 4 )alkyl, aryl, cycloalkyl, cycloalkylidene, ═N—ORa, ═O, —NRaRb, —COORc or cyano, wherein said (C 1 -C 4 )alkyl, aryl, cycloalkyl, or cycloalkylidene may optionally be substituted by one or more substituents selected from R2;
wherein R2 represents (C 1 -C 4 )alkyl;
wherein Ra and Rb independently represents (C 1 -C 4 )alkyl or aryl; and
wherein Re represents (C 1 -C 4 )alkyl;
and pharmaceutically acceptable salts, hydrates and solvates thereof;
with the proviso that if R1 represents alkyl or alkenyl, the combined length of R and R1 does not exceed that of a chain of seven carbon atoms,
and with the proviso that R and R1 in combination may not be a straight unbranched or unsubstituted alkyl chain or a straight unbranched or unsubstituted alkenyl chain,
and with the proviso that R, or R and R1 in combination is not trans-2-buten-2-yl, 3-methyl-2-buten-2-yl, but-2-yl, propen-2-yl or cis-2-buten-2-yl.
2. A compound according to claim 1 , wherein R is substituted by R1 in the alpha- or beta-position relative to the carbonyl-group.
3. A compound according to claim 1 , wherein R is substituted by R1 in the alpha-position relative to the carbonyl-group.
4. A compound according to claim 1 , wherein R is (C 1 -C 7 )alkyl.
5. A compound according to claim 4 , wherein R is ethyl, propyl, tent-butyl, isopropyl, 2-butyl, 3-pentyl or isobutyl.
6. A compound according to claim 1 , wherein R is (C 2 -C 7 )alkenyl.
7. A compound according to claim 6 wherein R is propenyl or ethenyl.
8. A compound according to claim 1 , wherein R1 is ethyl, methyl, phenyl, cyclohexyl, ═N—OCH 3 , —N(CH 3 )(C 6 H 5 ), —COOCH 3 or cyclohexylidene.
9. A compound according to claim 1 , wherein R1 is methyl.
10. A compound according to claim 1 , wherein R2 is methyl.
11. A compound according to claim 1 , said compound being:
Ingenol 3-(2-methyl-acrylate),
Ingenol 3-(3-methyl-butenoate),
Ingenol 3-(2-methylene-butyrate),
Ingenol 3-(2-methyl-propanoate),
Ingenol 3-(3-methyl-butanoate),
Ingenol 3-(3,3-dimethyl-butanoate),
Ingenol 3-(2-ethyl-butanoate),
Ingenol 3-(phenyl-acetate),
Ingenol 3-(2Z-(methoxycarbonyl)-acrylate),
Ingenol 3-(2-cyclohexylpropanoate),
Ingenol 3-((2Z)-2-methoxyimino-2-phenyl-acetate),
Ingenol 3-((2E)-2-methoxyimino-2-phenyl-acetate),
Ingenol 3-((Z)-2-methyl-3-(p-tolyl)prop-2-enoate),
Ingenol 3-((E)-2-phenylbut-2-eno ate),
Ingenol 3-(2,2-diphenylacetate),
Ingenol 3-(2-cyano-2-cyclohexylidene-acetate)
Ingenol 3-(2-(methyl(phenyl)amino)-2-oxo-acetate) or
pharmaceutically acceptable salts thereof.
12. A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable stereoisomer or salt thereof together with a pharmaceutically acceptable vehicle or excipient.
13. A pharmaceutical composition according to claim 12 , wherein the composition is suitable for topical administration.
14. A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable stereoisomer or salt thereof in combination with one or more other therapeutically active agents.